Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 27, 24 | -0.74 Decreased by -21.31% | -0.71 Decreased by -4.23% |
| Nov 13, 23 | -0.71 Decreased by -26.79% | -0.69 Decreased by -2.9% |
| Aug 14, 23 | -0.76 Decreased by -55.1% | -0.7 Decreased by -8.57% |
| May 15, 23 | -0.67 Decreased by -48.89% | -0.6 Decreased by -11.67% |
| Mar 29, 23 | -0.61 Decreased by -74.29% | -0.62 Increased by +1.61% |
| Nov 14, 22 | -0.56 Decreased by -115.38% | -0.5 Decreased by -12% |
| Aug 15, 22 | -0.49 Increased by +97.94% | -0.45 Decreased by -8.89% |
| May 16, 22 | -0.45 Increased by +96.48% | -0.28 Decreased by -60.71% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by N/A% | -20.41 M Decreased by -35.89% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by N/A% | -19.56 M Decreased by -50.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -19.02 M Decreased by -61.68% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -15.4 M Decreased by -42.59% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -15.02 M Decreased by -82.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -13.02 M Decreased by -110.61% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -11.77 M Decreased by -103.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -10.8 M Decreased by -288.39% | Decreased by N/A% Decreased by N/A% |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.